Investors
News / Events
Press Releases
April 16, 2019
Cortexyme Announces Phase 2/3 Clinical Trial Based On Transformational Understanding Of Alzheimer’s Disease
April 16, 2019
Cortexyme Announces Phase 2/3 Clinical Trial Based On Transformational Understanding Of Alzheimer’s Disease
April 16, 2019
Cortexyme Announces Phase 2/3 Clinical Trial Based On Transformational Understanding Of Alzheimer’s Disease
Events
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
Presentations
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019
March 25, 2019
Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019